Clinical Trial Update: Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating arsenic trioxide in combination with cytarabine for high-risk myelodysplastic syndrome and poor-prognosis acute myeloid leukemia; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• CYTARABINE (CYTARABINE)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED